Similar articles for PMID: 29405254

Year	Number of Results
1999	1
2003	1
2006	1
2007	1
2009	1
2013	1
2015	4
2016	13
2017	23
2018	52
2019	39
2020	30
2021	10
2022	3
2024	0

1

Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.

Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Fujimura T, Yamamoto Y, Hata H, Tanaka R, Yamaguchi K, Nonomura Y, Hirai I, Furudate S, Okuhira H, Imafuku K, Aoki M, Matsushita S. Fujisawa Y, et al. Br J Dermatol. 2018 Jul;179(1):213-215. doi: 10.1111/bjd.16427. Epub 2018 Apr 24. Br J Dermatol. 2018. PMID: 29405254 No abstract available.

2

MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma.

Nakahara S, Fukushima S, Okada E, Morinaga J, Kubo Y, Tokuzumi A, Matsumoto S, Tsuruta-Kadohisa M, Kimura T, Kuriyama H, Miyashita A, Kajihara I, Jinnin M, Ihn H. Nakahara S, et al. J Dermatol Sci. 2020 Jan;97(1):77-79. doi: 10.1016/j.jdermsci.2019.11.010. Epub 2019 Nov 30. J Dermatol Sci. 2020. PMID: 31843231 No abstract available.

3

Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.

Chasseuil E, Saint-Jean M, Chasseuil H, Peuvrel L, Quéreux G, Nguyen JM, Gaultier A, Varey E, Khammari A, Dréno B. Chasseuil E, et al. Acta Derm Venereol. 2018 Apr 16;98(4):406-410. doi: 10.2340/00015555-2872. Acta Derm Venereol. 2018. PMID: 29327065 Free article.

4

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.

Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, Cavalcanti E, Caracò C, Ascierto PA. Capone M, et al. J Immunother Cancer. 2018 Jul 16;6(1):74. doi: 10.1186/s40425-018-0383-1. J Immunother Cancer. 2018. PMID: 30012216 Free PMC article.

5

Prognostic role of neutrophil to lymphocyte ratio in advanced melanoma treated with anti-programmed death-1 therapy.

Minowa T, Kato J, Hida T, Horimoto K, Sato S, Sawada M, Uhara H. Minowa T, et al. J Dermatol. 2018 Sep;45(9):e250-e251. doi: 10.1111/1346-8138.14297. Epub 2018 Mar 23. J Dermatol. 2018. PMID: 29572922 No abstract available.

6

Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.

Kubo Y, Fukushima S, Inamori Y, Tsuruta M, Egashira S, Yamada-Kanazawa S, Nakahara S, Tokuzumi A, Miyashita A, Aoi J, Kajihara I, Tomita Y, Wakamatsu K, Jinnin M, Ihn H. Kubo Y, et al. J Dermatol Sci. 2019 Jan;93(1):33-40. doi: 10.1016/j.jdermsci.2018.10.001. Epub 2018 Oct 6. J Dermatol Sci. 2019. PMID: 30318169

7

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.

Stein JE, Soni A, Danilova L, Cottrell TR, Gajewski TF, Hodi FS, Bhatia S, Urba WJ, Sharfman WH, Wind-Rotolo M, Edwards R, Lipson EJ, Taube JM. Stein JE, et al. Ann Oncol. 2019 Apr 1;30(4):589-596. doi: 10.1093/annonc/mdz019. Ann Oncol. 2019. PMID: 30689736 Free PMC article. Clinical Trial.

8

Serum 5-S-cysteinyldopa behavior in the early phase of nivolumab treatment of 12 melanoma patients.

Omodaka T, Minagawa A, Uhara H, Wakamatsu K, Koizumi T, Yokokawa Y, Koga H, Okuyama R. Omodaka T, et al. J Dermatol. 2018 Nov;45(11):1340-1344. doi: 10.1111/1346-8138.14605. Epub 2018 Aug 25. J Dermatol. 2018. PMID: 30144152

9

Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma.

Ohashi H, Takeuchi S, Miyagaki T, Kadono T. Ohashi H, et al. Drug Discov Ther. 2020 Jul 15;14(3):117-121. doi: 10.5582/ddt.2020.03043. Epub 2020 Jun 27. Drug Discov Ther. 2020. PMID: 32595179 Free article.

10

Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma.

Sundahl N, Seremet T, Van Dorpe J, Neyns B, Ferdinande L, Meireson A, Brochez L, Kruse V, Ost P. Sundahl N, et al. Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):828-835. doi: 10.1016/j.ijrobp.2019.03.041. Epub 2019 Apr 3. Int J Radiat Oncol Biol Phys. 2019. PMID: 30951807 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

155 results

Results by year